Garth Cumberlidge, PhD, President & CEO
Garth is the President & Chief Executive Officer of SemaThera. Additionally, he is chairman of the Board of Directors of Eyevensys, a French biotechnology company developing novel non-viral gene therapy platform for visionthreatening ocular diseases. He is the former President and Chief Executive Officer of Mimetogen Pharmaceuticals Inc., a biotechnology company developing novel neuroprotective and neurostimulatory compounds for the treatment of ocular diseases. Prior to Mimetogen, Dr. Cumberlidge served as President & CEO of Qbiogene Inc., a company providing life sciences research products and custom cGMP manufacturing services to academic, biotechnology and pharmaceutical researchers worldwide. Dr. Cumberlidge holds degrees in Biochemistry and Genetics from the University of London (U.K.) and in Molecular Genetics from the Max-Planck-Institute for Molecular Genetics, Berlin (Germany).
Mike (Przemyslaw) Sapieha, PhD, Founder & Chief Scientific Officer
Mike (Przemyslaw) Sapieha is the Founder and Chief Scientific Officer of SemaThera. In addition, he is the Wolfe Professor of translational vision research and Canada Research Chair in retinal cell biology at the Maisonneuve-Rosemont Hospital Research Centre of the University of Montreal. He obtained his PhD in cell biology from University of Montreal and pursued postdoctoral fellowships at McGill and Harvard. His team made significant discoveries implicating deregulation of neuronal metabolism and cellular senescence in retinal vascular diseases such as diabetic retinopathy. Notably, they identified roles for guidance cues such as Semaphorins and Netrins in these diseases.
Véronique Bougie, MSc, Chief Operating Officer
Véronique Bougie has been involved in the creation and management of four biotech start-ups. Previously she was Director, Business Development in life science, Univalor LP, the tech transfer office of the University of Montreal and its affiliated institutions (CHUM, HMR, CHUSJ, IRCM, Ecole Polytechnique). Ms Bougie is a Certified Licensing Professional and holds a M.Sc. in virology and immunology at INRS-Armand-Frappier, undertook several training courses in intellectual property management & strategy and completed the Rutgers Business School Executive Education’s MiniMBA BioPharma Innovation.